Poniard announces positive top-line results from Phase I study of tumor drug
Poniard’s randomized, open-label, dose-ranging Phase I study was conducted at clinical sites in the US. The trial compared the bioavailability, pharmacokinetics, pharmacodynamics and safety of picoplatin administered orally
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.